Amgen (NSDQ:AMGN) said today that a committee for the European Medicines Agency has recommended that the regulatory body approve a label variation for its Neulasta product to include the Onpro on-body injector delivery device.
Neulasta’s Onpro kit includes a pre-filled syringe paired with a single-use on-body injector. The lightweight device is given to the patient on the same day as their chemotherapy regimen.
Get the full story at our sister site, Drug Delivery Business News.
The post EMA committee backs Amgen’s on-body injector for Neulasta appeared first on MassDevice.
from MassDevice http://ift.tt/2HPjFhm
Cap comentari:
Publica un comentari a l'entrada